Ascendis Pharma Reports Third Quarter 2024 Financial Results
YORVIPATH launching in U.S. with product availability expected mid-January 2025; ex-U.S. YORVIPATH revenue of €8.5 million in ...
manilatimes1h
Nova LifeStyle, Inc. Reports Third Quarter FY 2024 Results
LOS ANGELES, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Nova LifeStyle, Inc. (NASDAQ: NVFY) ("Nova LifeStyle” or the "Company”) today ...
Seeking Alpha5h
MBX Biosciences: Decent Potential For Lead Indication, But Need More Data
Ascendis Pharma’s (ASND) Palopegteriparatide is a once-daily PTH replacement therapy approved by the FDA and EMA and branded as Yorvipath. It's the only approved drug for HP, although it's not yet ...
Business Insider5h
BioCryst (BCRX) Receives a Buy from Bank of America Securities
The company’s shares opened today at $7.62. Ahmad covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Ascendis Pharma, and Ultragenyx Pharmaceutical. According to TipRanks, Ahmad ...
GlobalData on MSN6h
Metsera raises $215m in Series B round for weight loss candidates
Metsera has brought in over $500m in funding in just seven months as it looks to enter the competitive weight loss arena.
Ascendis Pharma Expands Capital to Fuel Growth
Ascendis Pharma (ASND) has released an update. Ascendis Pharma A/S has structured its capital to enable significant growth opportunities, with ...